03:33 , Aug 17, 2018 |  BC Week In Review  |  Financial News

Infectious company Aridis raises $26M in NASDAQ IPO

Infectious disease mAb company Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) raised $26 million on Aug. 13 through the sale of 2 million shares at $13 in an IPO on NASDAQ. Cantor Fitzgerald, Maxim Group, Laidlaw, Northland Securities...
16:31 , Aug 15, 2018 |  BC Innovations  |  Translation in Brief

Not your typical vaccine

In a July paper in the Proceedings of the National Academy of Sciences, University of Mississippi Medical Center researchers and colleagues identified conserved proteins in non-typeable Haemophilius influenzae that activate T cell responses to the...
23:50 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular Mouse studies suggest inhibiting the integrin CD29 could help treat vascular leakage caused by endotoxemia associated with sepsis. In a lipopolysaccharide (LPS)-induced mouse model of endotoxemia, an anti-CD29 mAb decreased vascular leakage and increased...
20:09 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; renal

INDICATION: Lupus; renal damage Patient sample and mouse studies suggest inhibiting CAMK4 could help treat lupus nephritis, focal segmental glomerulosclerosis (FSGS) and other podocytopathies. In kidney samples from lupus nephritis and FSGS patients, podocyte levels of...
19:06 , Jul 26, 2018 |  BC Innovations  |  Emerging Company Profile

The universe in an exosome

Versatope Therapeutics Inc. is using exosomes from commensal E. coli as the backbone of a universal influenza vaccine that should be cheaper and easier to manufacture than other vesicle-based vaccines. The company’s technology was developed by...
15:42 , Jul 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Gram-negative bacterial infection Cell culture studies suggest a 2,4-dinitrophenol (DNP)-polymyxin B conjugate could help treat Gram-negative bacterial infections. The conjugate consists of the generic membrane-disrupting antibiotic polymyxin B, which binds the LPS component lipid...
22:53 , Jul 20, 2018 |  BC Extra  |  Preclinical News

RIPK1 mutations in humans linked to IBD, arthritis

A study published in Science provides the first glimpse of clinical outcomes of receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) deficiency in humans, a target sought after by at least two companies trying to curb its...
18:56 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Forbion raises €270M, surpassing target for fourth fund

Forbion Capital Partners raised €270 million ($317.8 million) toward Forbion IV, surpassing its target of €250 million. The firm said the fund will have a "sharper focus" on biotech investments than Forbion Capital Fund III (FCF...
18:49 , Jul 13, 2018 |  BioCentury  |  Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
07:01 , Jul 11, 2018 |  BC Extra  |  Financial News

Forbion raises €270M, surpassing target for fourth fund

Forbion Capital Partners raised €270 million ($317.8 million) toward Forbion IV, surpassing its target of €250 million ($294.2 million). The firm said the fund will have a "sharper focus" on biotech investments than Forbion Capital Fund...